Inogen Inc Valuation – July 2018 $INGN

Company Profile (excerpt from Reuters): Inogen, Inc., incorporated on November 27, 2001, is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device. Its three portable product offerings, the Inogen One G4, Inogen One G3 and Inogen One G2, at approximately 2.8, 4.8 and 7.0 pounds with a single battery, respectively. Its Inogen One G4, Inogen One G3 and Inogen One G2 are sub-3, sub-5 and sub-10 pound portable oxygen concentrators, respectively. All of its Inogen One systems are equipped with Intelligent Delivery Technology. The Inogen At Home stationary oxygen concentrator allows it to access the non-ambulatory oxygen patient market and serves as a backup to its Inogen One system for ambulatory patients on its rental service.

Downloadable PDF version of this valuation:

ModernGraham Valuation of INGN – July 2018

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $4,523,365,268 Pass
2. Sufficiently Strong Financial Condition Current Ratio > 2 6.67 Pass
3. Earnings Stability Positive EPS for 10 years prior Fail
4. Dividend Record Dividend Payments for 10 years prior Fail
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end 12100.00% Pass
6. Moderate PEmg Ratio PEmg < 20 190.10 Fail
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 19.29 Fail
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 6.67 Pass
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 0.00 Pass
3. Earnings Stability Positive EPS for 5 years prior Pass
4. Dividend Record Currently Pays Dividend Fail
5. Earnings Growth EPSmg greater than 5 years ago Pass


Stage 2: Determination of Intrinsic Value

EPSmg $1.12
MG Growth Estimate 15.00%
MG Value $43.17
Opinion Overvalued
MG Grade C-
MG Value based on 3% Growth $16.26
MG Value based on 0% Growth $9.53
Market Implied Growth Rate 90.80%
Current Price $213.16
% of Intrinsic Value 493.75%

Inogen Inc is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability over the last ten years, and the poor dividend history, and the high PEmg and PB ratios. The Enterprising Investor is only concerned with the lack of dividends. As a result, all Enterprising Investors following the ModernGraham approach should feel comfortable proceeding with the analysis.

As for a valuation, the company appears to be Overvalued after growing its EPSmg (normalized earnings) from $0.29 in 2014 to an estimated $1.12 for 2018. This level of demonstrated earnings growth does not support the market’s implied estimate of 90.8% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on the Benjamin Graham value investing formula, returns an estimate of intrinsic value below the price.

At the time of valuation, further research into Inogen Inc revealed the company was trading above its Graham Number of $20.52. The company does not pay a dividend. Its PEmg (price over earnings per share – ModernGraham) was 190.1, which was above the industry average of 39.79. Finally, the company was trading above its Net Current Asset Value (NCAV) of $8.86.

Inogen Inc receives an average overall rating in the ModernGraham grading system, scoring a C-.

Stage 3: Information for Further Research

Net Current Asset Value (NCAV) $8.86
Graham Number $20.52
PEmg 190.10
Current Ratio 6.67
PB Ratio 19.29
Current Dividend $0.00
Dividend Yield 0.00%
Number of Consecutive Years of Dividend Growth 0

Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Balance Sheet Information 3/1/2018
Total Current Assets $251,054,000
Total Current Liabilities $37,667,000
Long-Term Debt $0
Total Assets $299,882,000
Intangible Assets $6,886,000
Total Liabilities $53,545,000
Shares Outstanding (Diluted Average) 22,295,000

Earnings Per Share History

EPS History
Next Fiscal Year Estimate $1.73
Dec2017 $0.96
Dec2016 $0.97
Dec2015 $0.56
Dec2014 $0.30
Dec2013 $0.68
Dec2012 $0.04

Earnings Per Share – ModernGraham History

EPSmg History
Next Fiscal Year Estimate $1.12
Dec2017 $0.78
Dec2016 $0.63
Dec2015 $0.41
Dec2014 $0.29
Dec2013 $0.24
Dec2012 $0.01

Recommended Reading:

Other ModernGraham posts about the company

Inogen Inc Valuation – Initial Coverage $INGN

Other ModernGraham posts about related companies

Tenet Healthcare Corp Valuation – June 2018 $THC
Universal Health Services Inc Valuation – June 2018 $UHS
Dentsply Sirona Inc Valuation – June 2018 $XRAY
IDEXX Laboratories Inc Valuation – June 2018 $IDXX
Hologic Inc Valuation – June 2018 $HOLX
Mettler-Toledo International Inc Valuation – June 2018 $MTD
Envision Healthcare Corp Valuation – June 2018 $EVHC
DaVita Inc Valuation – June 2018 $DVA
Danaher Corp Valuation – May 2018 $DHR
Agilent Technologies Inc Valuation – May 2018 $A


The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.